Search results for "antineoplastic"

showing 10 items of 2217 documents

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience

2014

Background: Optimally, secondary cytoreduction is acknowledged as a valid option in terms of oncologic outcome for patients with platinum-sensitive recurrent ovarian cancer. In cases of localized relapse, a laparoscopic approach has been attempted at various institutions, but studies on its role for this subset of patients still are limited. This report describes the authors' experience using laparoscopic secondary cytoreduction for patients with localized recurrent ovarian cancer. The results from a retrospective analysis of a prospective case series are reported. Methods: Between October 2011 and May 2013, 29 patients with localized recurrent ovarian cancer were selected for a laparoscopi…

Secondary cytoreductionmedicine.medical_treatmentTissue AdhesionsPostoperative ComplicationsLaparotomyLaparoscopyOvarian Neoplasmsmedicine.diagnostic_testMedicine (all)Middle Agedovarian cancerChemotherapy AdjuvantLymphatic MetastasisFemaleAdult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy; Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laparoscopy; Laparotomy; Length of Stay; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Monitoring; Intraoperative; Neoplasm Recurrence; Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Postoperative Complications; Retrospective Studies; Tissue AdhesionsAdultmedicine.medical_specialtyRecurrent ovarian cancer; Laparoscopy; Secondary cytoreductionOperative TimeAntineoplastic AgentsDisease-Free SurvivalLaparoscopicMonitoring IntraoperativeInternal medicineCarcinomamedicineHumansAgedNeoplasm StagingRetrospective StudiesLaparotomybusiness.industryGeneral surgeryCarcinomaRetrospective cohort studyLength of StayHepatologymedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIARecurrent Ovarian CancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalRecurrent ovarian cancerOvarian cancerbusinessFollow-Up StudiesAbdominal surgery
researchProduct

DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells.

2013

Recent studies have highlighted an apparently paradoxical link between self-renewal and senescence triggered by DNA damage in certain cell types. In addition, the finding that TP53 can suppress senescence has caused a re-evaluation of its functional role in regulating these outcomes. To investigate these phenomena and their relationship to pluripotency and senescence, we examined the response of the TP53-competent embryonal carcinoma (EC) cell line PA-1 to etoposide-induced DNA damage. Nuclear POU5F1/OCT4A and P21CIP1 were upregulated in the same cells following etoposide-induced G 2M arrest. However, while accumulating in the karyosol, the amount of OCT4A was reduced in the chromatin fract…

SenescenceCyclin-Dependent Kinase Inhibitor p21OCT4A/POU5F1Embryonal Carcinoma Stem CellssenescenceDNA RepairDNA repairDNA damagetumor cellsBiologyProtein Serine-Threonine Kinasesself-renewalHistonesAurora KinasesCell Line TumorReportAutophagyAurora Kinase BHumansTP53PhosphorylationRNA Small InterferingMolecular BiologyMitosisCellular SenescenceCyclin-Dependent Kinase Inhibitor p16EtoposideOvarian NeoplasmsEmbryonal Carcinoma Stem CellsCell BiologyG2-M DNA damage checkpointbeta-GalactosidasepluripotencyAntineoplastic Agents PhytogenicChromatinUp-RegulationG2 Phase Cell Cycle CheckpointsCheckpoint Kinase 2Cancer researchDNA damageFemaleRNA InterferenceRad51 RecombinaseTumor Suppressor Protein p53Cell agingOctamer Transcription Factor-3Developmental BiologyCell cycle (Georgetown, Tex.)
researchProduct

Proteomic analysis reveals a role for Bcl2-associated athanogene 3 and major vault protein in resistance to apoptosis in senescent cells by regulatin…

2014

Senescence is a prominent solid tumor response to therapy in which cells avoid apoptosis and instead enter into prolonged cell cycle arrest. We applied a quantitative proteomics screen to identify signals that lead to therapy-induced senescence and discovered that Bcl2-associated athanogene 3 (Bag3) is up-regulated after adriamycin treatment in MCF7 cells. Bag3 is a member of the BAG family of co-chaperones that interacts with Hsp70. Bag3 also regulates major cell-signaling pathways. Mass spectrometry analysis of the Bag3 Complex revealed a novel interaction between Bag3 and Major Vault Protein (MVP). Silencing of Bag3 or MVP shifts the cellular response to adriamycin to favor apoptosis. We…

SenescenceProteomicsCell cycle checkpointApoptosisBreast NeoplasmsBAG3BiochemistryAnalytical ChemistryMajor vault proteinCell Line TumorGene silencingHumansMolecular BiologyCellular SenescenceAdaptor Proteins Signal TransducingVault Ribonucleoprotein ParticlesMitogen-Activated Protein Kinase 1Antibiotics AntineoplasticMitogen-Activated Protein Kinase 3biologyResearchCell biologyApoptosisDoxorubicinbiology.proteinCancer researchSignal transductionApoptosis Regulatory ProteinsCell agingSignal TransductionMolecularcellular proteomics : MCP
researchProduct

The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors

2022

Salivary gland tumors represent a serious medical problem and new tools for differential diagnosis and patient monitoring are needed. Here, we present data and discuss the potential of molecular chaperones as biomarkers and therapeutic targets, focusing on Hsp10 and Hsp90. The salivary glands are key physiological elements but, unfortunately, the information and the means available for the management of their pathologies, including cancer, are scarce. Progress in the study of carcinogenesis has occurred on various fronts lately, one of which has been the identification of the chaperone system (CS) as a physiological system with presence in all cells and tissues (including the salivary gland…

Settore BIO/16 - Anatomia UmanaOrganic ChemistryAntineoplastic AgentsGeneral MedicineSettore MED/08 - Anatomia PatologicaSalivary Gland NeoplasmsSalivary GlandsCatalysisComputer Science ApplicationsDiagnosis DifferentialInorganic ChemistryHumanschaperone system differential diagnosis Ganetespib Hsp90 Hsp90 biomarker Hsp90 pathogenic negative chaperonotherapysalivary gland tumors Diagnosis Differential Humans Molecular Chaperones Salivary Glands Antineoplastic Agents Salivary Gland NeoplasmsHSP90 Heat-Shock ProteinsPhysical and Theoretical Chemistrysalivary gland tumors; chaperone system; Hsp90; Hsp90 pathogenic; negative chaperonotherapy; Ganetespib; Hsp90 biomarker; differential diagnosisMolecular BiologySpectroscopyMolecular Chaperones
researchProduct

Development of stimulus-sensitive electrospun membranes based on novel biodegradable segmented polyurethane as triggered delivery system for doxorubi…

2022

In this work, redox-sensitive polyurethane urea (PUU) based electrospun membranes have been exploited to chemically tether a pH-sensitive doxorubicin derivative achieved by linking a lipoyl hydrazide to the drug via a hydrazone linkage. First, the lipoyl-hydrazone-doxorubicin derivative labelled as LA-Hy-Doxo has been syn- thesized and characterized. Then, the molecule has been tethered, via a thiol-disulfide exchange reaction, to the redox-sensitive PUU (PolyCEGS) electrospun membrane. The redox-sensitive PolyCEGS PUU has been produced by using PCL-PEG-PCL polyol and glutathione-tetramethyl ester (GSSG-OMe)4 as a chain extender. The LA-Hy- Doxo tethered electrospun membrane has showed a du…

Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoDoxorubicinPolyurethanesPolyurethane Stimuli-responsive polymers Electrospun membrane Doxorubicin Lipoic acidCancer therapyHydrazonesHumansAntineoplastic AgentsMicellesBiomaterials Advances
researchProduct

Metabolic impact of Partial Volume Correction of [18F]FDG PET-CT oncological studies on the assessment of tumor response to treatment

2014

AIM: The aim of this work is to evaluate the metabolic impact of Partial Volume Correction (PVC) on the measurement of the Standard Uptake Value (SUV) from [18F]FDG PET-CT oncological studies for treatment monitoring purpose. METHODS: Twenty-nine breast cancer patients with bone lesions (42 lesions in total) underwent [18F]FDG PET-CT studies after surgical resection of breast cancer primitives, and before (PET-I) and after (PET-II) chemotherapy and hormone treatment. PVC of bone lesion uptake was performed on the two [18F]FDG PET-CT studies, using a method based on Recovery Coefficients (RC) and on an automatic measurement of lesion metabolic volume. Body-weight average SUV was calculated f…

Settore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniPhantoms ImagingReproducibility of ResultsAntineoplastic AgentsBone NeoplasmsBreast NeoplasmsMiddle AgedMultimodal ImagingBone and bonePositron-emission tomography Standardized uptake value Partial volume correction bone metastases therapy monitoringFluorodeoxyglucose F18[18F]FDG PET-CT oncologicalHumansRadiographic Image Interpretation Computer-AssistedFemaleNeoplasm MetastasisPositron-emission tomographyTomography X-Ray ComputedNeoplasm metastasiAged
researchProduct

Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?

2015

Introduction: Sorafenib is currently the only approved therapy in hepatocellular carcinoma (HCC). Alternative first- and second-line treatments are a significant unmet medical need, and several biologic agents have been tested in recent years, with poor results. Therefore, angiogenic pathways and the cytokine cascade remain possible targets in HCC. Recent studies suggest a role of epigenetic processes, associated with the initiation and development of HCC. In this field, DNA methylation, micro-RNAs (miRNAs) and tumor microenvironment cells became a possible new target for HCC treatment. Areas covered: This review explains the possible role of DNA methylation and histone deacetylase inhibito…

Settore MED/06 - Oncologia MedicaClinical BiochemistrytivantinibEpigenesis GeneticAntineoplastic Agentchemistry.chemical_compoundHistone Deacetylase InhibitorDrug DiscoveryTumor MicroenvironmentMolecular Targeted TherapyplateletmicroRNALiver Neoplasmshepatocellular carcinomaSorafenibVEGFLiver NeoplasmHepatocellular carcinomaDNA methylationMolecular MedicineepigeneticHumanmedicine.drugPhenylurea CompoundSorafenibNiacinamideCarcinoma HepatocellularAntineoplastic AgentsBiologymicroRNAmedicineAnimalsHumansEpigeneticsTivantinibPharmacologyTumor microenvironmentAnimalDrug Discovery3003 Pharmaceutical SciencePhenylurea CompoundsDNA Methylationmedicine.diseasedigestive system diseasesHistone Deacetylase InhibitorsMicroRNAschemistryDrug DesignImmunologyCancer researchHistone deacetylaseExpert opinion on therapeutic targets
researchProduct

Reactivity of antitumor coinage metal-based N-heterocyclic carbene complexes with cysteine and selenocysteine protein sites

2021

Abstract The reaction of the antitumor M(I)-bis-N-heterocyclic carbene (M(I)-NHC) complexes, M = Cu, Ag, and Au, with their potential protein binding sites, i.e. cysteine and selenocysteine, was investigated by means of density functional theory approaches. Capped cysteine and selenocysteine were employed to better model the corresponding residues environment within peptide structures. By assuming the neutral or deprotonated form of the side chains of these amino acids and by considering the possible assistance of an external proton donor such as an adjacent acidic residue or the acidic component of the surrounding buffer environment, we devised five possible routes leading to the binding o…

SilverAnticancer; Copper(I) complexes; DFT calculations; Gold(I) complexes; N-heterocyclic carbenes; Silver(I) complexesStereochemistryCoinage metalsAntineoplastic AgentsProtonationLigandsDFT calculationsBiochemistrySilver(I) complexesInorganic Chemistrychemistry.chemical_compoundDeprotonationProtein structureCoordination ComplexesCysteineN-heterocyclic carbenesDensity Functional Theorychemistry.chemical_classificationMolecular StructureSelenocysteineCopper(I) complexesSelenocysteineAmino acidAnticancerGold(I) complexesModels ChemicalchemistryThermodynamicsGoldCarbeneCopperCysteineJournal of Inorganic Biochemistry
researchProduct

New combinations for mantle cell lymphoma: concerted action needed.

2011

Sirolimusbusiness.industryLymphoma Mantle-Cellmedicine.diseaseArticleAntibodies Monoclonal Murine-DerivedOncologyAction (philosophy)Antineoplastic Combined Chemotherapy ProtocolsCancer researchMedicineHumansMantle cell lymphomabusinessRituximabThe Lancet. Oncology
researchProduct

Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update

2020

CTLA-4 and PD-1 play a key role in tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti-CTLA-4 and anti-PD-1 antibodies affect the interaction between tumor, antigen-presenting cells and T lymphocytes. Clinical studies of the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five-year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with …

Skin NeoplasmsDrug-Related Side Effects and Adverse ReactionsSide effectProgrammed Cell Death 1 ReceptorMedizinIpilimumabDermatologyPembrolizumabAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenImmune Checkpoint InhibitorsMelanomabusiness.industryMelanomamedicine.diseaseCombined Modality TherapyIpilimumabImmune checkpoint3. Good healthNivolumabCTLA-4ImmunologyImmunotherapyNivolumabbusinessmedicine.drug
researchProduct